1. Home
  2. UPBD vs RCUS Comparison

UPBD vs RCUS Comparison

Compare UPBD & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • RCUS
  • Stock Information
  • Founded
  • UPBD 1986
  • RCUS 2015
  • Country
  • UPBD United States
  • RCUS United States
  • Employees
  • UPBD N/A
  • RCUS N/A
  • Industry
  • UPBD Diversified Commercial Services
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UPBD Consumer Discretionary
  • RCUS Health Care
  • Exchange
  • UPBD Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • UPBD 1.5B
  • RCUS 1.2B
  • IPO Year
  • UPBD 1995
  • RCUS 2018
  • Fundamental
  • Price
  • UPBD $25.02
  • RCUS $11.53
  • Analyst Decision
  • UPBD Buy
  • RCUS Buy
  • Analyst Count
  • UPBD 4
  • RCUS 8
  • Target Price
  • UPBD $34.50
  • RCUS $20.71
  • AVG Volume (30 Days)
  • UPBD 587.5K
  • RCUS 747.7K
  • Earning Date
  • UPBD 10-30-2025
  • RCUS 11-05-2025
  • Dividend Yield
  • UPBD 6.24%
  • RCUS N/A
  • EPS Growth
  • UPBD 78.87
  • RCUS N/A
  • EPS
  • UPBD 1.79
  • RCUS N/A
  • Revenue
  • UPBD $4,481,986,000.00
  • RCUS $262,000,000.00
  • Revenue This Year
  • UPBD $9.99
  • RCUS N/A
  • Revenue Next Year
  • UPBD $8.44
  • RCUS N/A
  • P/E Ratio
  • UPBD $13.96
  • RCUS N/A
  • Revenue Growth
  • UPBD 7.49
  • RCUS 6.07
  • 52 Week Low
  • UPBD $19.65
  • RCUS $6.50
  • 52 Week High
  • UPBD $36.00
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 52.91
  • RCUS 61.05
  • Support Level
  • UPBD $24.39
  • RCUS $11.04
  • Resistance Level
  • UPBD $25.59
  • RCUS $12.05
  • Average True Range (ATR)
  • UPBD 0.65
  • RCUS 0.58
  • MACD
  • UPBD -0.01
  • RCUS 0.03
  • Stochastic Oscillator
  • UPBD 34.81
  • RCUS 67.05

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: